Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Disappearance of a Syndrome: Dressler’s Syndrome in the Era of Thrombolysis

Disappearance of a Syndrome: Dressler’s Syndrome in the Era of Thrombolysis The incidence of the post-myocardial infarction syndrome (Dressler’s syndrome) among thrombolized patients has not been established yet. To clarify this issue we prospectively studied 201 consecutive patients with acute myocardial infarction who had undergone recombinant tissue-type plasminogen activator therapy followed by 5 days of heparin administration. All patients were followed for at least 3 months for clinical signs of Dressler’s syndrome. None of the 148 patients (76%) who showed clinical signs of early reperfusion had Dressler’s syndrome. The sole patient in the group who manifested the syndrome developed it 3 weeks following extensive anterior myocardial infarction with no evidence of reperfusion. Although 4 patients manifested signs of early pericarditis, none developed the syndrome. We conclude that Dressler’s syndrome has in fact been rendered a rare phenomenon among patients who benefit from thrombolytic therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology Karger

Disappearance of a Syndrome: Dressler’s Syndrome in the Era of Thrombolysis

Download PDF
4 pages

Loading next page...
 
/lp/karger/disappearance-of-a-syndrome-dressler-s-syndrome-in-the-era-of-vXtyydxh25

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 1994 S. Karger AG, Basel
ISSN
0008-6312
eISSN
1421-9751
DOI
10.1159/000176683
Publisher site
See Article on Publisher Site

Abstract

The incidence of the post-myocardial infarction syndrome (Dressler’s syndrome) among thrombolized patients has not been established yet. To clarify this issue we prospectively studied 201 consecutive patients with acute myocardial infarction who had undergone recombinant tissue-type plasminogen activator therapy followed by 5 days of heparin administration. All patients were followed for at least 3 months for clinical signs of Dressler’s syndrome. None of the 148 patients (76%) who showed clinical signs of early reperfusion had Dressler’s syndrome. The sole patient in the group who manifested the syndrome developed it 3 weeks following extensive anterior myocardial infarction with no evidence of reperfusion. Although 4 patients manifested signs of early pericarditis, none developed the syndrome. We conclude that Dressler’s syndrome has in fact been rendered a rare phenomenon among patients who benefit from thrombolytic therapy.

Journal

Cardiology – Karger

Published: Jan 1, 1994

Keywords: Dressler’s syndrome; Thrombolysis, recombinant tissue-type plasminogen activator

There are no references for this article.